Amphastar Pharmaceuticals (NASDAQ:AMPH) Price Target Cut to $25.00 by Analysts at Piper Sandler

Key Points

• Amphastar Pharmaceuticals' price target has been reduced from $30.00 to $25.00 by Piper Sandler, maintaining a "neutral" rating on the stock, which indicates a potential upside of 15.63% from current levels.
• Multiple analysts have adjusted their price targets, with Wells Fargo lowering it to $35.00 and JPMorgan reducing theirs to $30.00, while the average target across analysts stands at $30.00.
• The stock currently trades at $21.62, with a market capitalization of approximately $1.02 billion and high volatility indicated by a beta of 0.76.

Amphastar Pharmaceuticals (NASDAQ:AMPH - Get Free Report) had its price objective cut by equities researchers at Piper Sandler from $30.00 to $25.00 in a report issued on Friday,Benzinga reports. The brokerage presently has a "neutral" rating on the stock. Piper Sandler's price objective points to a potential upside of 15.63% from the company's current price.

Several other research analysts also recently weighed in on AMPH. Wells Fargo & Company dropped their price target on Amphastar Pharmaceuticals from $40.00 to $35.00 and set an "overweight" rating for the company in a research note on Thursday, May 8th. JPMorgan Chase & Co. restated a "neutral" rating and set a $30.00 target price (down previously from $45.00) on shares of Amphastar Pharmaceuticals in a research report on Monday, May 12th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Amphastar Pharmaceuticals in a research note on Thursday, April 10th. Four equities research analysts have rated the stock with a hold rating and one has given a buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Hold" and an average price target of $30.00.

Amphastar Pharmaceuticals Stock Performance

NASDAQ AMPH opened at $21.62 on Friday. The company has a quick ratio of 2.02, a current ratio of 2.95 and a debt-to-equity ratio of 0.80. Amphastar Pharmaceuticals has a twelve month low of $20.39 and a twelve month high of $53.96. The business has a 50-day moving average price of $23.40 and a 200-day moving average price of $26.36. The firm has a market cap of $1.02 billion, a price-to-earnings ratio of 7.83 and a beta of 0.76.

Institutional Trading of Amphastar Pharmaceuticals

Hedge funds have recently modified their holdings of the company. Signaturefd LLC raised its stake in Amphastar Pharmaceuticals by 147.7% during the first quarter. Signaturefd LLC now owns 872 shares of the company's stock valued at $25,000 after purchasing an additional 520 shares in the last quarter. MassMutual Private Wealth & Trust FSB increased its holdings in shares of Amphastar Pharmaceuticals by 192.8% in the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 1,262 shares of the company's stock worth $29,000 after buying an additional 831 shares during the last quarter. Hantz Financial Services Inc. raised its position in shares of Amphastar Pharmaceuticals by 3,430.8% during the 2nd quarter. Hantz Financial Services Inc. now owns 1,377 shares of the company's stock valued at $32,000 after buying an additional 1,338 shares in the last quarter. IFP Advisors Inc bought a new position in shares of Amphastar Pharmaceuticals in the 1st quarter valued at about $34,000. Finally, GF Fund Management CO. LTD. purchased a new position in Amphastar Pharmaceuticals in the fourth quarter worth about $38,000. 65.09% of the stock is owned by hedge funds and other institutional investors.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.